[CAS NO. 26016-98-8] Fosfomycin calcium
PRODUCTS SPECIFICATIONS [26016-98-8]
DESCRIPTION [26016-98-8]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 176.12 |
| Molecular Formula | C3H5CaO4P |
| SMILES | C[C@H]1[C@@H](P([O-])([O-])=O)O1.[Ca+2] |
4 Publications Citing Use of MCE
Summary
Fosfomycin (MK-0955) calcium is a blood-brain barrier penetrating, broad-spectrum antibiotic by irreversibly inhibiting an early stage in cell wall synthesis. Fosfomycin calcium shows both in vivo and in vitro activity against a wide range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria [1] [2] .
In Vitro
Fosfomycin calcium is an epoxy antibacterial agent. Compared with other antibacterial agents, it acts by inhibiting the early process of cell wall synthesis
[1]
.
Fosfomycin calcium has bactericidal activity against a variety of gram-negative and gram-positive pathogens, including broad-spectrum production β-Bacteria of lactamase and carbapenemase, and against S. aureus strains with an inhibition rate of 90%
[1]
.
Fosfomycin calcium displays extensive tissue penetration, can be used to research of infections of the CNS, soft tissues, bone, lungs, and abscesses
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Fosfomycin calcium (80 mg/kg; i.v.-i.v. or i.v.-p.o.) displays the protective effect on the nephrotoxicity of double beckacin, and is not affected by different administration routes
[3]
.
Pharmacokinetic of Fosfomycin calcium in Rats
[4]
| Dibekacin Dose (mg) | V dss (l/kg) | β (min -1 ) | T 1/2 (min) | Urinary recovery (%) |
| 30 | 0.261 | 0.0244 | 28.4 | 85 |
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Fischer 344 rats [3] |
| Dosage: | 320 mg/kg |
| Administration: | Intramuscular injection, 5 schedules: 1 h, 0.5 h earlier than dibekacin, concomitantly, 0.5 h later and 1 h later; 11 days |
| Result: | Reduced polyuria, proteinuria, enzymes and cytosine caused by dibecacin (40 mg/kg), followed by the previous treatment. |
| Animal Model: | Dehydrated Wistar rat with acute renal failure (8-week-old) [4] |
| Dosage: | 120 mg/kg |
| Administration: | Intravenous injection; once |
| Result: |
Recovered the exclusion rate of rats basically to normal, and improved the nephrotoxicity parameters.
Protects proximal tubular lysosomes from aminoglycosides by inhibiting myeloid formation and protecting the integrity of lysosomal membrane of rats treated with double bekacin. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT05254808 | MJM Bonten|ZonMw: The Netherlands Organisation for Health Research and Development|Saltro|UMC Utrecht |
Urinary Tract Infections
|
September 6, 2021 | Phase 3 |
| NCT03697993 | National Institute of Allergy and Infectious Diseases (NIAID) |
Urinary Tract Infection
|
November 7, 2018 | Phase 4 |
| NCT05545137 | Benova (Tianjin) Innovative medicine Research Co., Ltd.|Greenpine Pharma Group Co., ltd. |
Uncomplicated Urinary Tract Infection
|
December 30, 2022 | Phase 3 |
| NCT05260554 | K?rklareli University |
Urinary Tract Disease|Cystitis|Antibiotic Reaction
|
January 26, 2022 | |
| NCT02639520 | Bionorica SE |
Urinary Tract Infection
|
December 2015 | Phase 3 |
| NCT01898338 | Miquel Pujol|Hospital Universitari de Bellvitge|Spanish Network for Research in Infectious Diseases |
Staph Aureus Methicillin Resistant Bacteremia
|
December 2013 | Phase 3 |
| NCT01969799 | Cardeas Pharma |
Pneumonia, Bacterial
|
December 2013 | Phase 2 |
| NCT04076436 | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla |
Complicated Urinary Tract Infection
|
October 21, 2019 | |
| NCT05055544 | University of Pecs |
Cystitis
|
October 2021 | Not Applicable |
| NCT03950544 | Shanghai 10th People´s Hospital |
Antibiotic Resistant Infection
|
January 1, 2019 | Early Phase 1 |
| NCT03868969 | Centre Hospitalier Universitaire de Besancon |
Urinary Tract Infections
|
April 2019 | Phase 2 |
| NCT03151603 | University Medical Center Goettingen |
Urinary Tract Infections
|
May 3, 2017 | Phase 4 |
| NCT02142751 | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|Spanish Network for Research in Infectious Diseases |
Infection Due to ESBL Escherichia Coli
|
July 2014 | Phase 3 |
| NCT04312360 | Zealand University Hospital|Costerton Biofilm Center|Reponex Pharmaceuticals A+S|Region Zealand |
Right-sided Colon Cancer|Right-sided Colon Adenoma
|
January 16, 2020 | Phase 2 |
| NCT03910673 | National Institute of Allergy and Infectious Diseases (NIAID) |
Bacterial Infection|Multiple-drug Resistance|Pathogen Resistance
|
June 27, 2019 | Phase 1 |
| NCT03176563 | University Medical Center Goettingen |
Urinary Tract Infections
|
May 3, 2017 | |
| NCT00976963 | University of Washington |
Urinary Tract Infection
|
September 2009 | Not Applicable |
| NCT03235947 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Laboratorios Senosiain, S.A. de C.V. |
Urinary Tract Infection|Asymptomatic Bacteriuria
|
September 7, 2016 | Phase 4 |
| NCT04979832 | Zealand University Hospital |
Pouchitis
|
September 6, 2021 | Phase 1|Phase 2 |
| NCT02570074 | Vance Fowler, M.D.|National Institute of Allergy and Infectious Diseases (NIAID)|Duke University |
Healthy Subjects
|
January 2016 | Phase 1 |
| NCT05311254 | Fundación para la Investigación Biosanitaria del Principado de Asturias|Instituto de Investigación Marqués de Valdecilla|Instituto de Salud Carlos III |
Febrile Neutropenia
|
March 14, 2022 | Phase 3 |
| NCT02218359 | Cardeas Pharma |
Pneumonia, Bacterial
|
October 2014 | Phase 2 |
| NCT04209192 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Laboratorios Senosiain, S.A. de C.V. |
Urinary Tract Infections|Bladder Cancer|Urologic Surgical Procedures
|
January 1, 2020 | Phase 2 |
| NCT00871104 | Juan A. Arnaiz|Hospital Clinic of Barcelona |
Infective Endocarditis
|
July 2009 | Phase 4 |
| NCT01297894 | Mahidol University |
Drug Safety
|
June 2010 | Phase 3 |
| NCT05211011 | Charite University, Berlin, Germany|Pro-Implant Foundation |
Prosthetic Joint Infection
|
January 23, 2018 | Phase 4 |
| NCT01966653 | University Hospital, Geneva|European Commission |
Urinary Tract Infections|Cystitis
|
October 2013 | Phase 4 |
| NCT03453177 | Drugs for Neglected Diseases|KEMRI-Wellcome Trust Collaborative Research Program|University of Oxford |
Neonatal SEPSIS
|
March 15, 2018 | Phase 2 |
| NCT02178254 | National Institute of Allergy and Infectious Diseases (NIAID) |
Pseudomonas Infection
|
August 2014 | Phase 1 |
| NCT03228108 | Radboud University Medical Center|ZonMw: The Netherlands Organisation for Health Research and Development |
Complication|Infection|Prostate Cancer
|
April 3, 2018 | Phase 4 |
| NCT03294395 | Public Health Service of Amsterdam|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
Gonorrhea
|
September 18, 2017 | Phase 3 |
| NCT01803191 | Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia|Hospital General Universitario Santa Lucía|Hospital General Universitario Los Arcos del Mar Menor |
Urinary Tract Infections
|
August 2012 | Phase 4 |
| NCT04959331 | Jordi Gol i Gurina Foundation|Balearic Islands Health Service (Ibsalut)|Instituto de Investigación Sanitaria Aragón|Gerencia de Atención Primaria, Madrid |
Urinary Tract Infections
|
November 2, 2021 | Phase 4 |
| NCT03260010 | Pro-Implant Foundation|Charite University, Berlin, Germany |
Prosthetic Joint Infection
|
January 15, 2018 | Phase 4 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H 2 O : 50 mg/mL ( 283.90 mM ; ultrasonic and adjust pH to 2 with HCl)
DMSO : < 1 mg/mL (insoluble or slightly soluble)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 5.6779 mL | 28.3897 mL | 56.7795 mL |
| 5 mM | 1.1356 mL | 5.6779 mL | 11.3559 mL |
| 10 mM | 0.5678 mL | 2.8390 mL | 5.6779 mL |
References
- [1] Falagas ME, et al. Fosfomycin. Clin Microbiol Rev. 2016 Apr. 29(2):321-47.
- [2] Dijkmans AC, et al. Fosfomycin: Pharmacological, Clinical and Future Perspectives. Antibiotics (Basel). 2017 Oct 31;6(4). pii: E24.
- [3] Inouye S, et al. Protective effect of fosfomycin on the experimental nephrotoxicity induced by dibekacin. J Pharmacobiodyn. 1982 Sep. 5(9):659-69.
- [4] Inouye S, et al. Mode of protective action of fosfomycin against dibekacin-induced nephrotoxicity in the dehydrated rats. J Pharmacobiodyn. 1982 Dec. 5(12):941-50.
Synonyms